Rosemary Mazanet
Director/Board Member at ONCTERNAL THERAPEUTICS, INC.
Net worth: 570 817 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nicholas Vita | M | 51 |
Argenis Capital Advisors LLC
 Argenis Capital Advisors LLC Investment ManagersFinance Argenis Capital Advisors LLC is an independent hedge fund manager headquartered in New York City. Founded in 2006, the firm provides investment advice to high net worth individual and institutional clients. | 12 years |
| David Hale | M | 75 | 27 years | |
| Michael Carter | M | 86 |
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 5 years |
| James Breitmeyer | M | 70 | 27 years | |
| David Hart | M | 47 | 8 years | |
| Richard Vincent | M | 61 | 7 years | |
| Steven J. Evans | M | - |
Oncolyze, Inc.
 Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | - |
| Jesse Channon | M | 40 | 5 years | |
| Rajesh Krishnan | M | 51 | 5 years | |
| Bryan Olson | M | 50 | 7 years | |
| Alison Worthington | F | 59 | 4 years | |
| Xin Nakanishi | M | 62 | 6 years | |
| Michael Abbott | M | 60 | 12 years | |
| Robert Wills | M | 70 | 5 years | |
| Michael Livingstone | M | - | - | |
| Chase Leavitt | M | 42 | 3 years | |
| Jonathan May | M | 57 | 5 years | |
| Jill DeSimone | F | 68 | 1 years | |
| Julie Hill | F | 78 | 3 years | |
| James Aloysius Kennedy | M | 70 | 2 years | |
| Charles Theuer | M | 60 | 6 years | |
| Jeffrey Clarke | M | 62 | 4 years | |
| William LaRue | M | 73 | 7 years | |
| John H. Abeles | M | 78 |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | - |
| Dan Kisner | M | 77 | 5 years | |
| Frank Savage | M | 85 | 4 years | |
| Pablo Urbaneja | M | - | 3 years | |
| David Sirolly | M | 49 | 3 years | |
| Salim Yazji | M | 55 | 3 years | |
| Lindsay Wilson | M | - | 4 years | |
| Lee Ann Evans | M | - | 2 years | |
| Alexander Zukiwski | M | 65 |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | - |
| Anita Wiseth | F | - | 3 years | |
| Lionel Carnot | M | 56 |
Oracle Partners LP
| 25 years |
| Guy Jacques Hussussian | M | - | - | |
| James L. Foght | M | 85 |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | - |
| Derek Watson | M | 53 | 2 years | |
| Richard V. McCloskey | M | - |
University of Pennsylvania Medical Center
| - |
| Peter Wilding | M | 89 |
University of Pennsylvania Medical Center
| 21 years |
| Alex Stojanovic | M | - |
Oncolyze, Inc.
Oncolyze, Inc. BiotechnologyHealth Technology Oncolyze, Inc. is a private company developing a novel technology for cancer treatment. The company is based in New York, NY and was founded by Steven J. Evans and John H. Abeles. The company's lead drug candidate targets the cancer cell membrane and selectively kills cancer cells and cancer stem cells while sparing normal cells, potentially providing a highly effective treatment with little to no side effects. The initial therapeutic target is acute myeloid leukemia (AML), a cancer with a low five-year survival rate. Oncolyze's drug has been shown to destroy leukemic cancer stem cells, disrupting current medical treatment. Steven J. Evans has been the CEO since incorporation. | 5 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Davis | M | 61 | 12 years | |
| Sergio Traversa | M | 63 |
Cactus Ventures, Inc.
 Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 1 years |
| Marc M. P. de Garidel | M | 66 | 15 years | |
| Diane S. Button | F | 73 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 6 years |
| Kathryn Falberg | F | 63 | 6 years | |
| Madhavan Balachandran | M | 73 | 20 years | |
| Dragan Cicic | M | 60 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 1 years |
| John V. Talley | M | 68 |
Cactus Ventures, Inc.
Cactus Ventures, Inc. Financial ConglomeratesFinance Cactus Ventures, Inc. operates as a blank check company. Cactus Ventures intends to locate and negotiate with a business entity for the merger of that target company into the company. The company was founded on October 6, 1997 and is headquartered in Carson City, NV. | 1 years |
| Steve H. Rouhandeh | M | 67 | 13 years | |
| John David Howard | M | 71 | 1 years | |
| Mark J. Ahn | M | 61 | 11 years | |
| Martin Simonetti | M | 66 | 7 years | |
| Mark Alvino | M | 56 | 14 years | |
| Esteban Cvitkovic | M | 74 | 5 years | |
| Domingo Rodriguez | M | 62 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 years |
| John Smither | M | 71 | 6 years | |
| Jason Shackelford | M | 48 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Igor Gimelshtein | M | 36 | 1 years | |
| Frans Gustaf Wuite | M | 64 | - | |
| Kenneth Robinson | M | 69 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Timothy Sear | M | 86 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 years |
| James Dalton | M | 61 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 9 years |
| Robert Karr | M | 75 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | 6 years |
| Jin Zhu Chen | M | 39 | 1 years | |
| Jeffrey G. Hesselberg | M | 65 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| Solomon David | M | 57 | 1 years | |
| Patricia A. Turney | F | 57 | 23 years | |
| J. Glass | M | 77 |
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | - |
| David Baltimore | M | 86 | 21 years | |
| Judith C. Pelham | F | 78 | 22 years | |
| Susan Lundeen Smuck | F | 57 | 12 years | |
| David Lacey | M | 71 | 17 years | |
| David Green | M | - | 11 years | |
| Andrew Knudten | M | - | 13 years | |
| Donna French | M | 59 | 15 years | |
| Gilbert M. Rishton | M | - | 9 years | |
| Daniel Flynn | M | 70 | - | |
| Wen Chen | M | 56 | - | |
| Randal A. Hassler | M | 66 | 12 years | |
| Warren Wayne Myers | M | 62 | 10 years | |
| Xue Ming Qian | M | 57 | 13 years | |
| Margaret E. Valeur-Jensen | M | 67 | 7 years | |
| William D. Welch | M | - | 5 years | |
| Peter García | M | 62 | 6 years | |
| Carol Gallagher | M | 59 | 8 years | |
| Larry Alan May | M | 74 | 15 years | |
| Susan Mahony | M | 59 | 4 years | |
| Lowell E. Sears | M | 73 | 8 years | |
| Daniel Vapnek | M | 85 | 15 years | |
| George A. Vandeman | M | 84 | 5 years | |
| Mark Moon | M | - | 6 years | |
| Gregory Stea | M | 66 | 9 years | |
| Richard Yeh | M | 56 | - | |
| Stephen H. Watkins | M | - | 6 years | |
| Pirow Bekker | M | 63 | 8 years | |
| Kathleen M. Wiltsey | F | 68 | 14 years | |
| Danute M. Bankaitis-Davis | M | - | 6 years | |
| Carl LeBel | M | 65 | 10 years | |
| William Richards | M | 63 | 23 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 99 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Rosemary Mazanet
- Personal Network
